SCHEMBL3487570

SCHEMBL3487570

CCc1cccc(Oc2ccc(N)c(CNC(=O)O)c2)c1

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MMP13 P45452 1/20 0.42
MAPK14 Q16539 1/20 0.41
FFAR1 O14842 3/20 0.41
MAPK1 P28482 2/20 0.41
L3MBTL1 Q9Y468 2/20 0.41
KDM4E B2RXH2 2/20 0.41
ALDH1A1 P00352 2/20 0.41
USP2 O75604 1/20 0.41
HPGD P15428 1/20 0.41
TSHR P16473 2/20 0.40
CYP1A2 P05177 1/20 0.40
CYP2D6 P10635 1/20 0.40
CYP2C9 P11712 1/20 0.40
CYP2C19 P33261 1/20 0.40
PPARG P37231 1/20 0.40
PPARD Q03181 1/20 0.40
PPARA Q07869 1/20 0.40
SMN1; SMN2 Q16637 2/20 0.40
TDP1 Q9NUW8 1/20 0.40
CTSD P07339 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3487573 0.89 MAPK14 (0.40) MAPK14MAPK1KDM4EALDH1A1HPGD
SCHEMBL3487214 0.86 ALDH1A1 (0.54) FFAR1MAPK1L3MBTL1ALDH1A1SMN1; SMN2
SCHEMBL3487614 0.85 SMN1; SMN2 (0.52) MMP13KDM4EALDH1A1USP2HPGD
SCHEMBL3487598 0.82 HTR2A (0.44) FFAR1CYP1A2CYP2D6CYP2C9CYP2C19
SCHEMBL3488473 0.82 MAPK14 (0.51) MAPK14PPARGPPARDPPARALTA4H
SCHEMBL3488176 0.82 TEAD4 (0.46) MMP13MAPK14ALDH1A1CYP1A2CYP2C9
SCHEMBL3488317 0.81 FFAR1 (0.47) MMP13MAPK14FFAR1L3MBTL1KDM4E
SCHEMBL3488320 0.81 FFAR1 (0.47) MMP13MAPK14FFAR1L3MBTL1KDM4E
SCHEMBL3488403 0.81 SMN1; SMN2 (0.42) MAPK1L3MBTL1ALDH1A1HPGDPPARG
SCHEMBL3488380 0.81 RAF1 (0.44) MMP13KDM4EALDH1A1SMN1; SMN2POLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2138484-B1 FUSED BICYCLIC HETEROARYL DERIVATIVES DAIICHI SANKYO CO LTD (JP) 2015-08-26 EP disclosed
US-20100048564-A1 FUSED BICYCLIC HETEROARYL DERIVATIVE DAIICHI SANKYO COMPANY, LIMITED (JP) 2010-02-25 US disclosed
EP-2138484-A1 FUSED BICYCLIC HETEROARYL DERIVATIVES Daiichi Sankyo Company, Limited (JP) 2009-12-30 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100048564-A1 FUSED BICYCLIC HETEROARYL DERIVATIVE PPARG, GPR119, PPARA MMP13 3505/4885MAPK14 1880/4885FFAR1 10/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.